E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
severely injured trauma patients with lactic acidosis due to hemorrhagic shock |
pazienti gravemente traumatizzati che presentano acidosi lattica a seguito dello shock emorragico |
|
E.1.1.1 | Medical condition in easily understood language |
trauma patients who are severely injured and bleeding |
pazienti traumatizzati gravemente feriti e con emoraggie |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Injuries, poisonings, and occupational diseases [C21] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10023676 |
E.1.2 | Term | Lactic acidosis |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050841 |
E.1.2 | Term | Hemorrhagic shock |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to evaluate the safety and efficacy of 250 mL MP4OX treatment compared to 250 mL of normal saline solution plus replacement doses if continued hemorrhage, in addition to standard treatment, in severely injured trauma patients with lactic acidosis due to hemorrhagic shock |
L'obiettivo principale è valutare la sicurezza e l'efficacia del trattamento con 250ml di MP4OX in confronto a 250 ml di soluzione fisiologica normale più dosi di rimpiazzo se continua l’emorragia, in aggiunta al trattamento standard, in pazienti gravemente traumatizzati che presentano acidosi lattica a seguito dello shock emorragico |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1)Informed consent obtained before any study-related activities (study-related activities are any procedure that would not have been performed as standard of care for the patient) 2)Trauma injury (blunt and/or penetrating) resulting in lactic acidosis due to hemorrhagic shock 3)Acidosis (blood lactate level ≥ 5 mmol/L; equivalent to 45 mg/dL) arterial or venous |
1) Consenso informato ottenuto il prima di qualsiasi attività associata allo studio; 2) Lesione traumatica (netta e/o penetrante) che porta a acidosi lattica secondaria allo shock emorragico; 3) Acidosi (livello di lattato nel sangue ≥ 5 mmol/l; equivalente a 45 mg/dl ) arteriosa o venosa |
|
E.4 | Principal exclusion criteria |
1)Massive injury incompatible with life 2)Normalization of lactate prior to dosing (≤ 2.2mmol/L) 3)Patients with evidence of severe traumatic brain injury as defined by ANY one of the following: a)Known non-survivable head injury or open brain injury b)Glasgow Coma Score (GCS) = 3, 4 or 5 c)Known AIS (head region) ≥ 4 shown by an appropriate imaging methodology d)Contemplated CNS surgery e)Abnormal physical exam indicative of severe CNS or any spinal cord injury above T5 level 4)Cardiac arrest prior to randomization 5)Age below the legal age for consenting 6)Estimated time from injury to randomization> 4 hours 7)Estimated time from hospital admission to randomization > 2 hours 8)Known pregnancy 9)Use of any oxygen carrier other than RBCs 10)Known previous participation in this study 11)Professional or ancillary personnel involved with this study 12)Known receipt of any investigational drug(s) within 30 days prior to study |
1) Lesione massiva incompatibile con la vita; 2) Normalizzazione del lattato prima della somministrazione (≤2,2mmol/l); 3) Pazienti con evidenze di grave lesione traumatica cerebrale come definito da UNA QUALSIASI delle seguenti condizioni: - Trauma cranico o ferita aperta del cervello che notoriamente hanno esito fatale, - Glasgow Coma Score (GCS) = 3, 4 o 5, - Noto AIS (regione cranica) ≥ 4 mostrato da un’appropriata tecnica di imaging, - Chirurgia del SNC contemplata, - Anomalie all’esame obiettivo indicative di grave lesione del SNC o qualsiasi lesione spinale al di sopra del livello T5; 4) Arresto cardiaco prima della randomizzazione; 5) Età inferiore alla maggiore età per fornire il consenso alla partecipazione; 6) Tempo previsto dal momento della lesione alla randomizzazione > 4 ore; 7) Tempo previsto dal momento lesione alla randomizzazione > 2 ore; 8)Gravidanza nota; 9)Uso di qualsiasi trasportatore di ossigeno diverso dagli RBC; 10) Nota partecipazione precedente a questo stesso studio; 11) Personale professionale o ausiliario coinvolto in questo studio; 12) Avere notoriamente ricevuto qualsiasi farmaco in fase investigativa entro i 30 giorni che precedono lo studio |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the proportion of patients discharged from hospital through day 28 and alive at the Day 28 Follow up visit |
L’endpoint primario di efficacia è la percentuale di pazienti dimessi dall’ospedale fino al giorno 28 e vivi alla visita di Follow up al Giorno 28 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 28 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Brazil |
Colombia |
Israel |
New Zealand |
Singapore |
South Africa |
Switzerland |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 18 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 18 |
E.8.9.2 | In all countries concerned by the trial days | 0 |